101 
Market Cap
Stock Chart
Biota - 30 day Poll
Recent BLOGS About Biota Add New
Latest Company News
|
HRV Phase II Trial Underway in Patients
PharmaLive - Jul 26, 2010 Melbourne, Australia — 26 July 2010 HRV Phase II trial underway in patients Biota Holdings Limited (ASX:BTA) today announced the commencement of a Phase II clinical trial of the antiviral drug ...
Biota Holdings targeting asthma market with anti-viral drug - Australian Life Scientist |
|
Biota Holdings Ltd. Commences Phase II Clinical Trial Of Antiviral Drug BTA798
Reuters Key Development - Jul 24, 2010 |
|
Royalties from Relenza for Q4 and F2010
PharmaLive.com - Jul 22, 2010 Melbourne, Australia — 22 July 2010 Biota Holdings Limited (ASX:BTA) today announced that it had received written notification from GlaxoSmithKline (GSK) that indicative royalties from Relenza ...
Relenza cash flow slows - The Age |
|
Australia, New Zealand Stocks: BHP, Biota, Downer, Qantas Airways, Vector
Bloomberg - Jul 22, 2010 By Lisa Pham and Shani Raja - Jul 22, 2010 Australia's S&P/ASX 200 Index lost 0.9 percent to 4,374.70 at the 4:10 pm close of trading in Sydney. New Zealand's NZX 50 Index retreated 0.7 percent to ...
Australia, NZ Stocks: BHP, Biota, Downer EDI, Qantas, Vector - BusinessWeek |
|
iSOFT Group Limited (ASX:ISF) Appoints Dr. James Fox As Deputy Chairman
ABN Newswire - May 31, 2010 iSOFT Group Limited (ASX:ISF), Australia's largest listed health information technology company today announced the appointment of Dr. James (Jim) Fox as Deputy Chairman. This decision affirms the ...
|
|
Biota Holdings Ltd. Completes Asset Purchase From MaxThera, Inc.
Reuters Key Development - Mar 4, 2010 |
|
Biota Holdings Ltd. Submits New Drug Application In Japan For CS-8958 With Daiichi Sankyo Company, Limited
Reuters Key Development - Feb 1, 2010 |
|
Biota Holdings Limited Acquires Antibacterial Assets Of Prolysis Limited; Also To Acquire Antibacterial Assets Of MaxThera, Inc.
Reuters Key Development - Nov 11, 2009 |
Website
Videos related to Biota
Company Profile
Biota is a leading anti-infective drug development company, based in Melbourne, Australia. Biota's initial success was the discovery of zanamivir (Relenza), the first-in-class neuraminidase inhibitor for the treatment and prevention of influenza. Zanamivir is licensed to GlaxoSmithKline and marketed as Relenza™. Relenza is used to treat seasonal influenza and is currently being stockpiled by various governments for defence against possible pandemic outbreaks of influenza.
Daiichi Sankyo: for the development of second generation influenza antivirals (called LANI or long-acting inhaled neuraminidase inhibitors). In 2009, Phase III trials for laninamivir in Asia were shown to be effective. Daiichi Sankyo, who co-own the LANI program have elected to market the drug in Japan.
In 2009, Phase IIa clinical trials of its lead human rhinovirus (HRV) drug achieved clinical proof-of-concept. The drug is aimed at prevention and treatment of one of the major causes of the common cold which is also thought to be a major cause of exacerbations in patients with chronic obstructive pulmonary disease and asthma.
Biota also has key partnerships with: Boehringer Ingelheim: where it has a licence and collaboration agreement to develop and commercialise Biota's novel nucleoside analogues, designed to treat hepatitis C virus (HCV) infections and potentially other diseases.
Cash Position 30th June 2009: $86 million
Related companies or competition:
- Tamiflu by Roche
- Gilead Sciences as listed on our USA sister website
Partners: GlaxoSmithKline (Relenza), Daichi Sankyo (long acting Relenza), Boehringer Ingelheim (HCV)
Possible Upcoming Events:
- possible licensing of long-acting Relenza for the US market
- working towards an apporval for long-acting Relenza as a drug in Japan following effective Phase III trials